HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Supplement Industry Capitol Hill Champion, Pivotal Drug Legislation Author Orrin Hatch Dies

Executive Summary

DSHEA, legislation Congress passed in 1994 establishing framework for FDA’s oversight of supplement manufacturing and marketing, doesn’t bear Hatch’s name. But in US consumer health products industry, his name is probably more frequently linked with DSHEA than with pivotal drug legislation he co-authored.

You may also be interested in...



Senate FDA User Fee Bill’s Mandatory Supplement Listing Provision Unites Industry In Opposition

Senate HELP Committee didn’t add amendments to user fee bill to protect confidential information and prevent FDA over-regulation in an MPL program, trade groups say. MPL proponents join opponents in saying language in S.4348 isn’t the answer.

Sen. Durbin Will Introduce US Mandatory Supplement Registration Bill

Sen. Durbin has been a critic of FDA’s regulation of VMS product market regulation, putting him at odds with industry stakeholders. But “Dietary Supplement Listing Act” he and Sen. Braun will introduce later in week has support of CHPA and CRN.

US Industry Recognizes Hatch As Driving Force Behind Creating The Modern VMS Product Market

Consumer health industry trade groups remember Orrin Hatch as the driving force behind expanding their markets and maintaining support on Capitol Hill.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS152444

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel